Thanks for extracting that info, so with GSK's cost of sales at 26%, here is the financial summary for Relenza.
From latest Annual report, Relenza Sales $A192m
GSK takes 93% less 26% cost of sales = 67% = $A128.64m
Biota takes 7% = $$A9m
What a slap in the face!!!!
PC, are you listening???? Contract out the manufacturing of LANI and recruit some serious Sales People. Biota will immediately become a $10+ stock and you immediately can start funding some serious pipeline R&D or look at some serious acquisitions.
Alternatively, give DS the manufacturing, but only if you don't get screwed on costs.
PC - better still, Directors, are you listening??
BTA Price at posting:
$1.29 Sentiment: Hold Disclosure: Held
